Neuronix Ltd.

8 articles about Neuronix Ltd.

• 

  FDA Panel Rejects Neuronix’s NeuroAD Device for Treating Alzheimer’s

  3/25/2019

  A U.S. Food and Drug Administration (FDA) advisory panel voted 14 to 0 against recommending Neuronix’s NeuroAD system for the treatment of mild to moderate Alzheimer’s disease.

• neuroAD™ Therapy System for Treatment of Mild-to-Moderate Alzheimer's Disease Considered by FDA Neurological Devices Advisory Committee

  3/22/2019

  Neuronix Ltd. announced that the U.S. Food and Drug Administration Neurological Devices Advisory Committee met on March 21 to consider data and receive public comment about the neuroAD™ Therapy System, a non-invasive medical device for the treatment of mild-to-moderate Alzheimer's disease.

• Neuronix Ltd. Announces The First Group Of Mild To Moderate Alzheimer Patients To Be Successfully Treated By The Neuroad Therapy System In London

  7/25/2017

• Neuronix Ltd. Reports Positive Results From Its Multi-Center Alzheimer's Study At The Clinical Trials In Alzheimer's Disease (CTAD) Conference

  1/4/2017

• Neuronix Ltd. Reports Positive Results In Its Multi-Center Alzheimer's Study And Submits Its Therapy System For FDA Clearance

  11/29/2016

• Neuronix Ltd. Offers New Alzheimer's Treatment

  10/30/2012

• Acorda Therapeutics Buying Morrisville-based Neuronix Ltd. for Up to $35 Million

  2/20/2012

• Neuronix Ltd. Release: Results of Successful Trial for Alzheimer Patients Applying Novel, Non-Invasive Technology to Be Revealed at Geneva Conference

  9/27/2010